Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma[J]. Am J Hematol, 2012,87(3):272-276. DOI: 10.1002/ajh.22273 . 返回引文位置Google Scholar 百度学术 万方数据 [9] Benboubker L , Dimopoulos MA , Dispenzieri A ,et al. Lenalidomide...
Clinical research of induced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma[J]. Journal of Experimental Hematology, 2013,21(2):441-445. DOI: 10.7534/j.issn.1009-2137.2013.02.038 . Goto CitationGoogle Scholar Baidu Scholar Wanfang Data [9] Berenson JR , Yellin O...
based induction and maintenance regimens and IV zole-dronic acid (ZOL) and oral ciodronate (CLO) in 1960 patients with newly diagnosed multiple myeloma... Morgan,J Gareth - 《Blood》 被引量: 73发表: 2012年 Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myelom...
DVd Superior to Vd Regardless of Prior Lines of Therapy in MyelomaJason HoffmanPharmD
, a human IgG魏 monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma. ...
:1·495· 2.2对肾功能的影响 本研究BDT方案组较改良VAD方案组起效快,缓解率 BDT方案组中3例治疗前伴有肾功能损害的患者,治疗后 高,总有效率达92.3%。BDT方案组患者的主要不良反应为周 均有明显改善,其中2例尿毒症患者经2个疗程化疗后未行血 围神经病变,发生率为54%,多为指尖麻木,无一例因严重周 液透析...
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor Introduction: Daratumumab (D) is a human monoclonal antibody targeting CD38 that is approved as monotherapy and in combination wit...
I soon found that if I couldn't help their pain quickly they would go somewhere else. Other patients would stay with me for years and I grew to like them, but I felt guilty when I didn't really make a change in their chronic pain....
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial Pts have completed a median of 4 cycles (range: 0-8) with a median of 3.2 months of follow up (range: 0-9.7). During the phase 1 portion, ...
a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Background Immunomodulatory drugs (IMiD), such as thalidomide and lenalidomide (LEN) and its newest derivative pomalidomide (POM), have shown great promise....